Label: CLINDAMYCIN PHOSPHATE- clindamycin phosphate solution
CLINDAMYCIN PHOSPHATE- clindamycin phosphate lotion
CLINDAMYCIN PHOSPHATE- clindamycin phosphate gel

  • NDC Code(s): 59762-3728-1, 59762-3728-2, 59762-3728-3, 59762-3743-1, view more
    59762-3743-2, 59762-3744-1
  • Packager: Greenstone LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application Authorized Generic

Drug Label Information

Updated 05/14

If you are a consumer or patient please visit this version.

  • SPL UNCLASSIFIED SECTION

    For External Use

    Close
  • DESCRIPTION

    Clindamycin phosphate topical solution and clindamycin phosphate topical lotion contain clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate topical gel contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram. Each clindamycin phosphate topical solution pledget applicator contains approximately 1 mL of topical solution.

    Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

    The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water.

    The gel contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.

    The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.

    The structural formula is represented below:

    Chemical Structure

    The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate).

    Close
  • CLINICAL PHARMACOLOGY

    Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

    Cross resistance has been demonstrated between clindamycin and lincomycin.

    Antagonism has been demonstrated between clindamycin and erythromycin.

    Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

    Clindamycin activity has been demonstrated in comedones from acne patients. The mean concentration of antibiotic activity in extracted comedones after application of clindamycin phosphate topical solution for 4 weeks was 597 mcg/g of comedonal material (range 0–1490). Clindamycin in vitro inhibits all Propionibacterium acnes cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.

    Close
  • INDICATIONS AND USAGE

    Clindamycin phosphate topical solution, clindamycin phosphate topical gel and clindamycin phosphate topical lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS.)

    Close
  • CONTRAINDICATIONS

    Clindamycin phosphate topical solution, clindamycin phosphate topical gel and clindamycin phosphate topical lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

    Close
  • WARNINGS

    Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

    Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

    When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

    Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridium difficile. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin in vitro. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

    Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

    Close
  • PRECAUTIONS

    General

    Clindamycin phosphate topical solution contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth.

    Clindamycin phosphate topical products should be prescribed with caution in atopic individuals.

    Drug Interactions

    Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.

    Pregnancy

    Teratogenic effects—Pregnancy Category B

    In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy.

    Clindamycin should be used during the first trimester of pregnancy only if clearly needed.

    Nursing Mothers

    It is not known whether clindamycin is excreted in human milk following use of clindamycin phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

    Pediatric Use

    Safety and effectiveness in pediatric patients under the age of 12 have not been established.

    Geriatric Use

    Clinical studies for Cleocin T did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

    Close
  • ADVERSE REACTIONS

    In 18 clinical studies of various formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

    Number of Patients Reporting Events
    Treatment Emergent
    Adverse Event
    Solution
    n=553(%)
    Gel
    n=148(%)
    Lotion
    n=160(%)
    # not recorded
    *
    of 126 subjects
    Burning 62 (11) 15 (10) 17 (11)
    Itching 36 ( 7) 15 (10) 17 (11)
    Burning/Itching 60 (11) # (−) # (−)
    Dryness 105 (19) 34 (23) 29 (18)
    Erythema 86 (16) 10 ( 7) 22 (14)
    Oiliness/Oily Skin 8 ( 1) 26 (18) 12* (10)
    Peeling 61 (11) # (−) 11 ( 7)

    Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

    Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

    Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

    Close
  • OVERDOSAGE

    Topically applied clindamycin phosphate can be absorbed in sufficient amounts to produce systemic effects. (See WARNINGS.)

    Close
  • DOSAGE AND ADMINISTRATION

    Apply a thin film of clindamycin phosphate topical solution, clindamycin phosphate topical lotion, clindamycin phosphate topical gel, or use a clindamycin phosphate topical solution pledget for the application of clindamycin phosphate twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.

    Lotion: Shake well immediately before using.

    Pledget: Remove pledget from foil just before use. Do not use if the seal is broken. Discard after single use.

    Keep all liquid dosage forms in containers tightly closed.

    Close
  • HOW SUPPLIED

    Clindamycin phosphate topical solution containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:

    30 mL applicator bottle—NDC 59762-3728-1

    60 mL applicator bottle—NDC 59762-3728-2

    Carton of 60 single-use pledget applicators—NDC 59762-3728-3

    Clindamycin phosphate topical gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes:

    30 gram tube—NDC 59762-3743-1

    60 gram tube—NDC 59762-3743-2

    Clindamycin phosphate topical lotion containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following size:

    60 mL plastic squeeze bottle—NDC 59762-3744-1

    Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

    Protect from freezing.

    Close
  • SPL UNCLASSIFIED SECTION

    Rx only

    Logo

    LAB-0048-7.0
    April 2014

    Close
  • PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Solution

    NDC 59762-3728-2
    60 mL

    GREENSTONE® BRAND

    clindamycin
    phosphate
    topical
    solution, USP

    1%*

    Solution for topical use
    only

    Rx only

    PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Solution
    Close
  • PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Solution

    NDC 59762-3728-2
    60 mL

    GREENSTONE® BRAND

    clindamycin
    phosphate
    topical
    solution, USP

    1%*

    Solution for topical use
    only

    Rx only

    PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Solution
    Close
  • PRINCIPAL DISPLAY PANEL - Pledget Packet

    NDC 59762-3728-3
    1 Pledget

    GREENSTONE® BRAND

    clindamycin
    phosphate
    topical
    solution, USP

    1%*

    Pledget for topical use only

    Rx only

    PRINCIPAL DISPLAY PANEL - Pledget Packet
    Close
  • PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Lotion

    NDC 59762-3744-1
    60 mL

    GREENSTONE® BRAND

    clindamycin
    phosphate
    topical lotion

    1%*

    For topical use
    only

    Rx only

    PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Lotion
    Close
  • PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Lotion

    NDC 59762-3744-1
    60 mL

    GREENSTONE® BRAND

    clindamycin
    phosphate
    topical
    lotion

    1%*

    For topical use only

    Rx only

    PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Lotion
    Close
  • PRINCIPAL DISPLAY PANEL - 60 gram Tube Label

    NDC 59762-3743-2
    60 gram

    GREENSTONE® BRAND

    clindamycin phosphate
    topical gel

    1%*

    For topical use only

    Rx only

    Store at controlled room temperature 20° to 25°C (68° to 77°F)
    [see USP]. Protect from freezing.

    For external use only. Avoid contact with eyes.

    See crimp of tube for Expiration Date and Lot Number.

    DOSAGE AND USE: See accompanying prescribing information.

    *Each gram contains clindamycin phosphate equivalent to 10 mg
    (1%) of clindamycin. Also contains allantoin, carbomer 934P,
    methylparaben, polyethylene glycol 400, propylene glycol, sodium
    hydroxide, and purified water.

    G
    Distributed by:
    Greenstone LLC, Peapack, NJ 07977

    PRINCIPAL DISPLAY PANEL - 60 gram Tube Label
    Close
  • PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton

    NDC 59762-3743-2
    60 gram

    GREENSTONE® BRAND

    clindamycin phosphate topical gel

    1%*

    For topical use only

    Rx only

    PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton
    Close
  • INGREDIENTS AND APPEARANCE
    CLINDAMYCIN PHOSPHATE 
    clindamycin phosphate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:59762-3728
    Route of Administration TOPICAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 10 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    ISOPROPYL ALCOHOL  
    PROPYLENE GLYCOL  
    WATER  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:59762-3728-1 1 in 1 CARTON
    1 30 mL in 1 BOTTLE
    2 NDC:59762-3728-2 1 in 1 CARTON
    2 60 mL in 1 BOTTLE
    3 NDC:59762-3728-3 60 in 1 CARTON
    3 1 mL in 1 PACKET
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA AUTHORIZED GENERIC NDA050537 06/20/1980
    CLINDAMYCIN PHOSPHATE 
    clindamycin phosphate lotion
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:59762-3744
    Route of Administration TOPICAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 10 mg  in 1 mL
    Inactive Ingredients
    Ingredient Name Strength
    CETOSTEARYL ALCOHOL  
    GLYCERIN  
    ISOSTEARYL ALCOHOL  
    METHYLPARABEN  
    SODIUM LAUROYL SARCOSINATE  
    STEARIC ACID  
    WATER  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:59762-3744-1 1 in 1 CARTON
    1 60 mL in 1 BOTTLE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA AUTHORIZED GENERIC NDA050600 05/31/1989
    CLINDAMYCIN PHOSPHATE 
    clindamycin phosphate gel
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:59762-3743
    Route of Administration TOPICAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN 10 mg  in 1 g
    Inactive Ingredients
    Ingredient Name Strength
    ALLANTOIN  
    CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)  
    METHYLPARABEN  
    POLYETHYLENE GLYCOL 400  
    PROPYLENE GLYCOL  
    SODIUM HYDROXIDE  
    WATER  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:59762-3743-1 1 in 1 CARTON
    1 30 g in 1 TUBE
    2 NDC:59762-3743-2 1 in 1 CARTON
    2 60 g in 1 TUBE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA AUTHORIZED GENERIC NDA050615 01/07/1987
    Labeler - Greenstone LLC (825560733)
    Registrant - Pfizer Inc (113480771)
    Establishment
    Name Address ID/FEI Business Operations
    Chongqing Carelife Pharmaceutical Co., Ltd 531132009 API MANUFACTURE(59762-3744, 59762-3728)
    Establishment
    Name Address ID/FEI Business Operations
    Pharmacia and Upjohn Company 829076566 ANALYSIS(59762-3743, 59762-3744), API MANUFACTURE(59762-3743, 59762-3744, 59762-3728), LABEL(59762-3743, 59762-3744), MANUFACTURE(59762-3743, 59762-3744), PACK(59762-3743, 59762-3744)
    Establishment
    Name Address ID/FEI Business Operations
    Zoetis P & U LLC 078822438 ANALYSIS(59762-3728), MANUFACTURE(59762-3728), PACK(59762-3728)
    Close